A Phase 3 Randomized, Double-Blind, Placebo-Controlled Study to Investigate the Efficacy and Safety of Once Weekly Eloralintide in Adult Participants With Persistent Obesity or Overweight Treated With a Weekly Incretin, With and Without Type 2 Diabetes
Eli Lilly and Company
Summary
The main purpose of this study is to evaluate the efficacy and safety of eloralintide compared with placebo in participants with persistent obesity or overweight, with or without type 2 diabetes, and on stable incretin background therapy. Participation in the study will last about 80 weeks.
Eligibility
- Age range
- 18+ years
- Sex
- All
- Healthy volunteers
- No
Inclusion Criteria: * Are on stable incretin therapy at screening * With persistent obesity or overweight defined as: * ≥30 kg/m2 OR * ≥27 kg/m2 with at least one existing obesity related complication at screening: * hypertension * dyslipidemia * obstructive sleep apnea * cardiovascular disease (for example, ischemic cardiovascular disease, New York Heart Association Functional Class I-III heart failure), or * type 2 diabetes * Have a stable body weight (\<5% body weight change) at screening Exclusion Criteria: * Have a prior or planned surgical treatment for obesi…
Interventions
- DrugEloralintide
Administered SC
- DrugPlacebo
Administered SC
Locations (178)
- Birmingham Clinical ResearchBirmingham, Alabama
- RIO Clinical Trials - PhoenixPhoenix, Arizona
- Headlands Research - ScottsdaleScottsdale, Arizona
- Novak Clinical Research - Tucson - North La Cholla BoulevardTucson, Arizona
- Irvine Clinical ResearchIrvine, California
- Scripps Whittier Diabetes InstituteLa Jolla, California